Skip to main content
Marlyn (Krampitz) Mayo, MD, Gastroenterology, Dallas, TX

MarlynJean(Krampitz)MayoMD

Gastroenterology Dallas, TX

Hepatology & Liver Transplantation

Professor of Medicine, University Tex SW Dallas

Dr. Mayo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mayo's full profile

Already have an account?

  • Office

    5323 Harry Hines Blvd
    Dallas, TX 75390
    Phone+1 214-645-8600
    Fax+1 214-645-0596

Education & Training

  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1993 - 1996
  • University of California (Irvine)
    University of California (Irvine)Residency, Internal Medicine, 1990 - 1993
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - Present
  • TX State Medical License
    TX State Medical License 1992 - 2026
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Fellow (AGAF) American Gastroenterological Association, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases  
    Marlyn (Krampitz) Mayo, MD, Hepatology

Authored Content

  • The Liver Meeting's Highlights and LowlightsNovember 2023

Press Mentions

  • Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin Deficiency
    Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin DeficiencyOctober 11th, 2024
  • Study Outlines Risk Factors for Autoimmune Hepatitis After Liver Transplant
    Study Outlines Risk Factors for Autoimmune Hepatitis After Liver TransplantMay 20th, 2022
  • CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
    CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary CholangitisNovember 11th, 2021
  • Join now to see all

Grant Support

  • Ursodeoxycholic Acid (UDCA) In Primary Biliary CirrhosisNational Center For Research Resources2007
  • UDCA Amp;Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2007
  • Treatment Of Metabolic PruritisNational Center For Research Resources2004–2007
  • UDCA &Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2006
  • Longitudinal Studies Of Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
  • 1treatment Of Cholestatic Pruritus With SertralineNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
  • Role Of CD40-CD40 Ligand In Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
  • Role Of CD40 Ligand In Primary Biliary CirrhosisNational Center For Research Resources1998–2002

Committees

  • Member, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present

Professional Memberships